Enhanced TCR footprint by a novel glycolipid increases NKT-dependent tumor protection by ASPESLAGH, SANDRINE et al.
 
 
biblio.ugent.be 
 
The UGent Institutional Repository is the electronic archiving and dissemination platform for all 
UGent research publications. Ghent University has implemented a mandate stipulating that all 
academic publications of UGent researchers should be deposited and archived in this repository. 
Except for items where current copyright restrictions apply, these papers are available in Open 
Access. 
 
This item is the archived peer‐reviewed author‐version of: 
Title:  
Enhanced TCR footprint by a novel glycolipid increases NKT‐dependent tumor protection 
 
Author(s):  Sandrine Aspeslagh, Marek Nemčovič, Nora Pauwels, Koen Venken, Jing Wang, Serge
Van Calenbergh, Dirk M. Zajonc and Dirk Elewaut 
 
 
Source: JOURNAL OF IMMUNOLOGY (2013), 191 (6) ,2916‐2925 DOI: 
10.4049/jimmunol.1203134 
Fo
r P
ee
r R
ev
iew
. D
o n
ot 
dis
trib
ute
. D
es
tro
y a
fte
r u
se
.
Enhanced TCR footprint by a novel glycolipid increases NKT 
dependent tumor protection. 
Running Title: Effects of a novel glycolipid with enhanced NKTCR footprint 
 
Sandrine Aspeslagh*§, Marek Nemčovič†§, Nora Pauwels‡, Koen Venken*, Jing Wang†, Serge 
Van Calenbergh‡, Dirk M. Zajonc†¶ and Dirk Elewaut*¶     
   
 
*Laboratory for Molecular Immunology and Inflammation, Department of Rheumatology, Faculty 
of Medicine and Health Sciences, Ghent University, Ghent, Belgium. 
†Division of Cell Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, 
USA 
‡Laboratory for Medicinal Chemistry, Faculty of Pharmaceutical Sciences, Ghent University, 
Ghent, Belgium 
 
§These authors contributed equally 
¶These authors shared supervision of the work 
 
¶To whom correspondence should be addressed: 
Dirk Elewaut, MD, PhD, Laboratory for Molecular Immunology and Inflammation, Department of 
Rheumatology, Ghent University, De Pintelaan 185, 9000 Ghent, Belgium.   Phone +32(9)3322240, 
Fax. +32(9)3323803. Email: Dirk.elewaut@ugent.be 
Dirk M. Zajonc, PhD, Division of Cell Biology, La Jolla Institute for Allergy and Immunology, 
9420 Athena Cir, La Jolla, CA 92037, USA. Phone +1(858)7526605, Fax. +1(858)7526985. Email: 
dzajonc@liai.org  
i 
Fo
r P
ee
r R
ev
iew
. D
o n
ot 
dis
trib
ute
. D
es
tro
y a
fte
r u
se
.
Abstract 
NKT cells, a unique type of regulatory T cells, respond to structurally diverse glycolipids presented 
by CD1d.  While it was previously thought that recognition of glycolipids such as α-GalCer by 
NKTCR obeys a key-lock principle, it is now clear this interaction is much more flexible. Here, we 
report the structure-function analysis of a series of novel 6”-OH analogues of α-GalCer with more 
potent anti-tumor characteristics.  Surprisingly, one the novel carbamate analogues, PyrC- α-
GalCer, formed novel interactions with the NKTCR.  This was associated with an extremely high 
level of Th1 polarization and superior anti-tumor responses.  These data highlight the in vivo 
relevance of adding aromatic moieties to the 6”-OH position of the sugar and additionally show that 
judiciously chosen linkers are a promising strategy to generate strong Th1 polarizing glycolipids 
through increased binding either to CD1d or NKTCR. 
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Introduction 
NKT cells are a subset of regulatory T cells that are involved in different pathological processes, 
ranging from autoimmunity to protection against tumors and bacterial infections (1).  NKT cell 
activation results in cytotoxicity, proliferation and also rapid cytokine production (within several 
hours), which subsequently activate several bystander immune cells (NK cells, dendritic cells, B 
cells, etc).  They have the capacity to produce both Th1 and Th2 cytokines and to modulate 
production by bystander cells. As such they have the ability to lead to Th biased responses under 
certain conditions. Although recently a lot of studies have been performed to unravel the 
mechanism for Th1/Th2 polarization (2-7), much remains to be uncovered.   
These innate-like T cells recognize glycolipids in the context of CD1d, which is a monomorphic 
MHC I like molecule that accommodates the lipid tails of the glycolipid in two hydrophobic 
pockets (A’ and F’) and presents the sugar head to the NKTCR. The proto ype iNKT-cell activating 
glycolipid is alpha-galactosylceramide (α-GalCer) whose chemical structure consists of a 26 carbon 
acyl chain and a phytosphingosine chain alpha anomerically linked to galactose.  Although initially 
iNKT cell research was mainly focused on this antigen, the list of novel glycolipids that are able to 
induce iNKT cell activation is continuously growing and includes very diverse bacterial antigens 
and endogenously expressed glycolipids, in addition to newly synthesized antigens (8, 9).   
The iNKT cell TCR is semi-invariant as it contains a conserved V14 chain in mice and V24 in 
human that both re-arrange with J18, while the Vβ chain is more variable. However, only 
germline encoded residues are important for the recognition of a glycolipid (10).  Although the 
TCR plays an important role for initial recognition of the CD1d-glycolipid complex, the strength of 
a Th1 polarized iNKT cell dependent activation seems to be more determined by the stability of the 
CD1d-glycolipid complex.  Previously we showed that NU- α-GalCer induces a structural change 
within the A’ roof of CD1d to which it binds with its hydrophobic 6”-naphthylurea group, leading 
to the so called third anchor model (7).  However extra binding strength of a glycolipid can also be 
achieved through alterations of the lipid tails (11, 12). The altered sphingosine chain of a plakoside 
analog was shown to increase the contact surface area with CD1d within the F’-pocket (6).  
Additionally it was shown that several acyl chain altered glycolipids can induce superior anti-cancer 
effects compared to α-GalCer and this was also linked to increased CD1d avidity (13). OCH on the 
other hand, has a shorter sphingosine chain (C9 instead of C18) and is therefore not able to induce 
the formation of the F’ roof in CD1d which affects the recognition by the NKTCR and thus its 
antigenicity (5, 14).  Last but not least crystallographic analysis of bacterial glycosyl-diacylglycerol 
lipids, as well as iGb3, which is a beta-anomeric tri-hexose containing sphingolipid self-antigen 
demonstrated that the TCR was able to “bulldoze” the three sugar groups over the CD1d-surface, 
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thus allowing the TCR to bind to the CD1d-glycolipid complex with its conserved footprint (15-
18).  For iGb3, this mechanism induces the last “anchor” sugar to bind to CD1d, however this 
doesn’t appear to happen to Gb3, which only differs by an altered linkage of the last sugar, because 
the position of the terminal sugar of Gb3 likely does not favor the formation of this additional 
anchor to CD1d (17). However, a similar, yet energetically unfavorable linker can be enforced in 
Gb3 through mutation of the TCR to reach sufficiently high auto-reactivity for CD1d (18). Besides 
its role in enhancing Th1 polarization, the stability of the CD1d-glycolipid complex also seems to 
determine the antigenicity of certain glycolipids for iNKT cells.  It was demonstrated for α-C-
GalCer, a well-known Th1 polarizing glycolipid with anti-tumor properties, that its complex with 
CD1d had a much longer half-life in vivo than the corresponding CD1d- α-GalCer complexes (5).   
Therefore structural features that enhance the binding stability between a glycolipid and CD1d seem 
to enhance both its antigenicity and its Th1 polarizing properties.  
Our previous data suggested that the formation of an extra anchor between a glycolipid and CD1d 
confers to stronger anti-tumoral responses in vivo.  However, the Th1 polarizing strength seemed to 
be critically dependent on the nature and length of the linker between C-6” of the galactose and the 
aromatic group.  BnNH-GSL-1’, an analogue that is characterized by an aromatic moiety that is 
located one atom closer to the galactose ring, was shown to exhibit weaker TCR affinity and 
decreased antigenicity. Despite the fact that this glycolipid also carries an amide linker, similar to 
the urea linker of NU- α-GalCer, it does not form an additional anchor with CD1d, likely as a result 
of the different linker length (7).  To explore the structural modifications that are required for the 
formation of the third anchor, three novel 6”-OH altered glycolipids were synthesized containing a 
carbamate linker, which has the same length as NU- α-GalCer but increased flexibility.  They are 
able to induce superior Th1 responses in mice and also activate human iNKT cells.  In contrast to 
most Th1 polarizing analogs the Th1 polarization potency did not only depend on the induction of a 
different Th1/Th2 polarization balance but also on a much higher induction of Th1 cytokines 
compared to α-GalCer, which was independent of the mode of administration.  We show that in 
analogy to NU- α-GalCer these carbamates display an increased binding stability for CD1d 
compared to α-GalCer, further emphasizing the relevance of this model in iNKT cell driven 
responses.  Additionally we demonstrate that one glycolipid exhibits better anti-tumor activity than 
NU- α-GalCer. Surprisingly, structural characterization of two of the potent carbamate glycolipids 
revealed that none of the aromatic groups form the third anchor to the degree observed for NU- α-
GalCer. Instead, the most potent Th-1 skewing glycolipid PyrC- α-GalCer does form an additional 
“anchor” with the TCR, leading to highest observed TCR binding affinity of all studied α-GalCer 
analogs to date but equal to that of α-GalCer itself. 
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Material and Methods  
Synthetic glycolipids 
Glycolipids were synthesized in the lab of Medicinal Chemistry (19). α-C-GalCer was kindly 
provided M.Tsuji (Aaron Diamond AIDS Research Center, NY, USA) and the NIH Tetramer Core 
Facility.  Lyophilized glycolipids were dissolved in pure DMSO (Sigma) at 10 mg/mL 
concentration and stored at -20˚C. Glycolipids were further solubilized by adding PBS (Invitrogen) 
or vehicle (96 mg/mL sucrose, 10 mg/mL sodium deoxycholate, 0,05 % Tween 20), warming to 
80°C for 20 minutes, sonication for 10 minutes.   
Cell Lines 
The murine iNKT hybridoma N38-2C12 (Vα14Vβ8.2b) was provided by L. Brossay (20) (Brown 
University, Providence, RI, USA). Cells were cultured in DMEM (Sigma) supplemented with 10% 
fetal calf serum (Invitrogen), 1% glutamine (Sigma), 1% penicillin streptomycin (Sigma), and 2-
mercaptoethanol (Sigma) (called cDMEM hereafter).  B16 melanoma cells were cultured in 
advanced RPMI (Sigma) supplemented with 10% fetal calf serum (Invitrogen), 1% glutamine 
(Sigma) and 1% penicillin streptomycin (Sigma).  They were harvested using cell dissociation 
buffer, which was washed away twice first using the medium and second with PBS.  400 000 cells 
were IV injected within 30 minutes after harvest into the tail vein.  
Isolation and expansion of BMDCs. 
BMDCs were isolated from the mouse bone marrow as described previously (21).  
Mice 
C57BL/6 and CD45.1 mice were in house bred (in accordance with the general recommendations 
for animal breeding and housing) or purchased from the Harlan Laboratory, Jα18-knockout mice on 
the C57BL/6 background were kindly provided by M. Taniguchi (22) (RIKEN, Tsurumi, 
Yokohama, Japan). Experiments were conducted according to the guidelines of the Ethical 
Committee of Laboratory Animals Welfare of Ghent University.  Mice used for experiments were 
between 5 and 12 weeks old.  
In vivo tumor model  
Within 30 minutes after harvesting, a dose of 2x105 or 4x105 cells B16 cells were inoculated 
intravenously (tail vein). Mice were killed 14 days later, the lungs were removed, and surface 
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metastases were counted with the aid of a dissecting microscope. 
In Vitro and In Vivo Activation of iNKT Cells 
For in vitro stimulation, murine iNKT hybridoma cells at 5x104 cells/well in 96-well plates were 
stimulated with the 105 cells/well glycolipid pulsed BMDCs in cDMEM for 4, 16 or 24 hours at 
37˚C, and levels of murine IL-2 secretion were determined by ELISA.  
For in vivo activation of iNKT cells C57BL/6 mice were either intraperitoneally injected with 5 µg 
glycolipid (dissolved in PBS) or intravenously with 6x104 or 1x104 glycolipid pulsed BMDCs.  
Isolation of human PBMCs and iNKT cells 
Human iNKT cells from healthy adult individuals were sorted and expanded as described 
previously (7).  PBMCs were isolated by means of density centrifugation, incubated overnight in 
the presence of indicated glycolipids (100 ng/ml), washed and irradiated (40 Gy).  Subsequently, 
5x104 iNKT cells were stimulated with 105 glycolipid pulsed autologous PBMCs in RPMI 1640 
media supplemented with 10% human AB serum (Lonza), 1% sodium pyruvate, 1% nonessential 
amino acids and 1% penicillin/streptomycin (all from Invitrogen).  Supernatants were collected 
after 24hrs of culture and cytokine levels were determined by means of cytometric Bead Arrays 
(CBA) following the manufacturer’s instructions (BD). 
Isolation of murine lymphocytes  
Spleen cells were isolated as previously described (23). Lymphocytes were isolated at the interface 
and washed, depleted with an anti-CD3 kit (Miltenyi) and resuspended in staining buffer containing 
saturating amount of anti-Fcγ Receptor type II/type III monoclonal antibodies (Miltenyi Biotec, 
Sunnyvale, CA).  Hereafter cells were stained with fluorochrome-conjugated mAbs (all from 
eBioscience) directed against the described antigens.  Live cells (exclusion with DAPI) were 
acquired on a FACSCanto (BD) flow cytometer and analyzed using FlowJo (Tree Star) software. 
Surface Plasmon Resonance experiments 
Glycolipids were dissolved in DMSO at 1 mg/ml and stored at -20oC. SPR studies were conducted 
using a Biacore 3000 as reported previously (24). Briefly, biotinylated birA-tagged mCD1d protein 
was loaded o/n with 6-times molar excess of glycolipids as previously reported (16) and 500 – 600 
RU of mCD1d-glycolipids complexes were captured on a streptavidin sensor chip surface (GE 
Healthcare). TCR protein was diluted in detergent-free running buffer (10 mM Hepes, 150 mM 
NaCl, and 3 mM EDTA, pH 7.4). The TCR was injected in serial dilutions (0, 0.0156 – 2 μM) for 
1.5 – 3 min at 30 μl/min to measure the association phase, while dissociation was continued for 45 
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min at 25oC. A reference surface containing “empty” CD1d was generated in flow channel one of 
the streptavidin sensor chip and its TCR binding response was subtracted from the other 
sensorgrams before calculating binding kinetics using a simple Langmuir 1:1 model in the BIA 
evaluation software version 4.1. Experiments were performed three times, each using a different 
TCR preparation.  
 
Crystallization and Structure Determination 
The ternary mCD1d-lipid-mTCR complexes using the lipids 4ClPhC-α-GalCer and PyrC-α-GalCer 
were prepared as described previously for NU-α-GalCer (7) and purified by size exclusion 
chromatography (SEC) using Superdex S200 10/300 GL (GE Healthcare). Both mCD1d-4ClPhC-α-
GalCer-mTCR and mCD1d-PyrC-α-GalCer-mTCR complexes were concentrated to 3.5 mg/ml in 
SEC buffer (50 mM Hepes, pH 7.5, 150 mM NaCl). Crystals were grown at 22.3oC by sitting drop 
vapor diffusion while by mixing 0.5 μl mCD1d-4ClPhC-α-GalCer-mTCR and 0.5 μl precipitate 
(20% PEG 4000, 0.2 M sodium thiocyanate) or by mixing 1 μl mCD1d-PyrC-α-GalCer-mTCR and 
1 μl precipitate (20% PEG 4000, 0.2 M di-ammonium hydrogen citrate), respectively.  
Crystals were flash-cooled at 100 K in mother liquor containing 30% glycerol. Diffraction data 
from a single crystal were collected at the Stanford Synchrotron Radiation Laboratory beamlines 9-
2 (mCD1d-4ClPhC-α-GalCer-mTCR) and 11-1 (mCD1d-PyrC-α-GalCer-mTCR), and were 
processed with the HKL2000 (25) and iMosflm (26) software to 3.0 Å, and 2.8 Å resolution, 
respectively. The mCD1d-4ClPhC-α-GalCer-mTCR crystal belongs to orthorhombic space group 
C2221 with cell parameters a = 79.28 Å, b = 191.86 Å, and c = 151.59 Å. The mCD1d-PyrC-α-
GalCer-mTCR crystal also belongs to space group C2221 with cell parameters a= 78.97 Å, b= 
191.40 Å, and c= 151.22 Å.   
The asymmetric unit contains one mCD1d-glycolipid-TCR molecule with estimated solvent content 
of 57.3 % based on a Matthews’ coefficient (Vm) of 2.88 A3/Da for 4ClPhC-α-GalCer and 56.9 % 
(VM) of 2.86 A3/Da for PyrC-α-GalCer. Crystal structures were determined by molecular 
replacement using MOLREP (27) as part of the CCP4 suite (28).  Protein coordinates from mCD1d-
iGB3-mTCR (from Protein Data Bank code 3RZC), as the search model, with the ligand removed, 
were used for molecular replacement (MR) for mCD1d-PyrC-α-GalCer-mTCR. The protein 
mCD1d coordinates from the mCD1d-iGB3 structure (from PDB 2Q7Y) and the mouse Vα14Vβ8.2 
TCR (from PDB 3QUY) coordinates were used for mCD1d-4ClPhC-α-GalCer-mTCR structure 
determination by MR. The REFMAC glycolipid libraries, were created using the Dundee ProDRG2 
server (29). After the MR solutions for both crystal structures were obtained, containing both 
mCD1d and mTCR, the model was rebuilt into σA –weighted 2Fo-Fc and Fo-Fc difference electron 
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density maps using the program COOT (30). Final refinement steps were performed using the 
translation, libration and screw axis (TLS) procedure in REFMAC(31) with five anisotropic 
domains (α1-α2 domain of mCD1d, including carbohydrates and glycolipids, α3-domain, β2m, 
variable domain, and constant domain of mTCR). The mCD1d-PyrC-α-GalCer-mTCR structure has 
the final Rcryst  = 19.13% and Rfree = 23.94% and was refined to 2.8 Å, while mCD1d-4ClPhC-α-
GalCer-mTCR was refined to 3.00 Å with a final Rcryst= 18.59% and Rfree= 22.84%. The high 
quality of both models was confirmed with the program Molprobity (32).  
 
Statistical analysis 
The statistical test used throughout this study was Kruskal-Wallis test with Dunn’s multiple 
comparison test or Mann Whitney U test (unpaired, two-sided) unless otherwise stated.  Data was 
analyzed using Excel (Microsoft) and Graphpad Prism 5.  
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Results 
Previously we have shown that α-GalCer analogs with alterations at the 6” position of the sugar 
head group are potent inducers of iNKT cell dependent IFN-γ production.  It was suggested that this 
would depend on the length of the linker between the sugar and the aromatic moiety.  
Crystallographic analysis of the tri-molecular complex with NU-α-GalCer showed that the latter 
makes an additional anchor to CD1d thereby stabilizing the interaction with CD1d (7).  In NU-α-
GalCer this linker is urea-based. However, if the chemical nature of the linker is critically important 
in determining the strong iNKT cell response was still unclear. From a synthesis point of view, a 
6”-O-based instead of a 6”-N-based derivatisation, could significantly improve the accessibility of 
6”-derivatives, since the route towards the former modification is typically 3 steps shorter.  To 
explore this enigma, three novel glycolipids were synthesized containing a carbamate-based linker 
instead of the urea (Figure 1) using a recently reported synthesis, which allows to selectively 
derivatise the 6”-OH, after regioselective opening of a 4”,6”-O-benzylidene ring (33).   
Carbamates are strong Th1 polarizers in vivo 
To assess the antigenicity of these carbamate analogues and their ability to induce Th1-skewing, 
mice were bled at 16 hours after i.p. glycolipid exposure because this is known to afford peak levels 
of IFN-γ, the hallmark Th1 cytokine.  Strikingly, all carbamate-linked glycolipids induced 
significantly higher IFN-γ levels than NU-α-GalCer and α-GalCer (Figure 1). In this setting, NU-α-
GalCer induced comparable or slightly lower IFN-γ production compared to α-GalCer.  IFN-γ  
production in response to glycolipid dependent iNKT cell activation is known to be dependent on 
IL-12 (34-36), which was therefore analyzed. As expected also IL-12 production was significantly 
higher for the carbamate-based glycolipids compared to α-GalCer.  However, only PyrC-α-GalCer 
was capable of inducing significantly higher IL-12 levels than NU-α-GalCer.  Administration of 
these novel glycolipids to Jα18-/- mice, which lack iNKT cells, did not induce any cytokine 
production, th reby excluding non-specific effects (Supplementary Figure 1).   
Next we examined if the glycolipid pulsed BMDCs behave similarly in vivo.  For cytokine analysis 
we bled the mice at several time points after injection.  We focused on IFN-γ and IL-12 secretion.  
Again at 16 hours both carbamates induced a significantly higher IFN-γ secretion compared to NU-
α-GalCer (which in this context is also significantly higher than α-GalCer) (Figure 2).  Strikingly 
for PyrC-α-GalCer the IFN-γ level increased up to 24 hours after injection in contrast to 4ClPhC-α-
GalCer and NU-α-GalCer.  Similarly IL-12 secretion was very high with PyrC-α-GalCer and even 
after 24 hours markedly higher than for NU-α-GalCer.  Furthermore, PyrC-α-GalCer and the other 
6”-OH altered glycolipids were also able to induce Th1-biased cytokine secretion (more IFN-γ and 
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IL-12 and less IL-4 and IL-13 compared to α-GalCer) in cultures of purified human iNKT cells 
(Figure 3 and data not shown).  A similar trend was seen with human peripheral blood mononuclear 
cells (PBMCs) (data not shown) highlighting the conserved nature of the Th polarization. 
6”-OH analogs modulate the co-stimulatory landscape 
Expression of co-stimulatory markers at the cell surface is linked to cytokine polarization because 
this determines the degree of activation of bystander cells such as NK cells, whose IFN-γ 
production is responsible for Th1 polarized cytokine profile (37).  For α-C-GalCer, it has been 
shown that expression of CD40 is essential for IL-12 and subsequent NK cell dependent IFN-γ 
production (3).  Additionally OX40L upregulation by DCs has been found important for α-GalCer 
dependent tumor killing (38).  Here we show that PyrC-α-GalCer, which induces the highest levels 
of IL-12, induces early CD40 and OX40L upregulation on spleen DCs (CD11c CD11b double 
positive) both quantitatively and qualitatively (Supplementary Figure 2). ICOSL expression has 
been related to production of Th2 cytokines by MZB cells (39) and was shown to be important for 
cytokine production and survival of CD4 positive iNKT cells (40). The shifts in ICOSL expression 
were overall minimal, so the exact relationship between ICOSL expression and the superior Th1 
polarization by PyrC-α-GalCer remains to be determined.  Glycolipid stimulation of iNKT cells 
leads to CD28 expression, and induces CD80 and CD86 expression at the dendritic cell surface, 
which is required for induction of IL-12 by dendritic cells (41).  This was confirmed here as all 
glycolipids including α-GalCer induced upregulation of both CD80 and CD86.   
 
TCR affinity and stability of the CD1d- glycolipid complex 
iNKT cell polarization is a matter of debate and it has been shown that uptake by different cells can 
also affect the outcome (42, 43).  To avoid these host dependent parameters we set up a simple in 
vitro model, which consists of co-cultures of glycolipid pulsed bone marrow dendritic cells and an 
iNKT cell hybridoma (i.c. 2C12 containing a Vβ8.2 TCR (44)).  IL-2 production is used as a read-
out for TCR affinity for the whole CD1d-glycolipid complex.  Here the carbamates, NU-α-GalCer 
and α-C-GalCer induce higher IL-2 levels (Figure 4).  To confirm this we also measured 
intracellular IL-2 production in 2C12 cells already 4 hours after co-culture, where a similar result 
was obtained (Figure 4).  It was reported that bone marrow dendritic cells (BMDCs) can also 
produce IL-2 (45), however intracellular IL-2 staining of BMDCs was negative (data not shown).  
Because IL-2 production is a downstream event of TCR signaling we analyzed TCRβ expression.  
In vivo it is well known that iNKT cells internalize their TCR upon antigen recognition (46).  Figure 
Fo
r P
ee
r R
ev
iew
. D
o n
ot 
dis
trib
ute
. D
es
tro
y a
fte
r u
se
.
4 suggests that TCR internalization also occurs in vitro and correlates well with the intracellular IL-
2 production.  
However, IL-2 production and TCR triggering are the result of both molecular TCR affinity and 
CD1d stability.  Therefore, we assessed the equilibrium binding constants (KD) of the TCR towards 
the different glycolipids presented by CD1d, using surface plasmon resonance.  Overall the data 
show similar affinities for the tested glycolipids PyrC-α-GalCer (KD=25 nM), α-GalCer (KD=26 
nM), NC-α-GalCer (KD=37 nM) and 4ClPhC-α-GalCer (KD=49.3 nM) (Table I). Thus in contrast to 
BnNH-GSL-1’ the glycolipid presentation by CD1d and/or the glycolipid interaction with the TCR 
is not significantly affected by the carbamate linked aromatic groups.  While 4ClPhC--GalCer 
shows a 2-fold reduced binding affinity (49 nM vs. 25 nM), the structurally related PyrC--GalCer 
has a binding affinity equal to that of GalCer (25 nM). Therefore, the slightly different 6”-OH 
modifications also translate into only marginally different binding affinities of the TCR, suggesting 
similar binding chemistries with the TCR. Secondly, we investigated the role of CD1d-glycolipid 
stability, which has recently been shown to be important for antigenic iNKT responses (6, 7, 13).  
We used a cellular assay to determine the binding stability of the novel glycolipids. Bone marrow 
dendritic cells were loaded with 100 ng/mL glycolipid during 20 hours.  After removal of the free 
glycolipid, cells were left in appropriate medium for several time intervals (ranging from 4h to 
48h).  Dissociated glycolipid was removed and co-culture with 2C12 cells was initiated.  IL-2 
production in the medium was used as a surrogate marker for remaining CD1d with glycolipid.  The 
strong Th1 polarizing α-C-GalCer, characterized by a higher binding stability to CD1d, was also 
included into this assay.  IL-2 levels were normalized to the values of 4 hours after wash off to 
exclude the effect of TCR affinity.  Figure 5B clearly shows that all 6”-OH analogs and α-C-GalCer 
behave very similarly and have a much slower decay compared to α-GalCer.  We conclude that all 
tested Th1 analogs have a similar stability with CD1d in vitro, which is much higher than for the 
CD1d-α-GalCer complex.   
 
Crystal structure of the mCD1d-PyrC-α-GalCer-TCR and mCD1d-4ClPhC-α-GalCer-TCR 
ternary complexes 
We previously reported the structural details of how another potent Th1 skewing glycolipid, NU-α-
GalCer interacts with CD1d and the TCR of iNKT cells (7). In that case the NU-group faces down 
into the CD1d binding groove to form an additional anchor with CD1d, leading to increased CD1d 
stability. We, therefore sought to determine whether the glycolipids PyrC-α-GalCer and 4ClPhC-α-
GalCer follow a similar binding mode, since their 6” modifications are connected to the galactose 
of α-GalCer via a more flexible carbamate linker (Figure 1). We determined the crystal structures of 
the ternary complexes CD1d-PyrC-α-GalCer-TCR and CD1d-4ClPhC-α-GalCer-TCR to resolutions 
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of 2.8 Å and 3 Å, respectively (Supplementary table 1 and Figure 6)ii.  Surprisingly, while the 
binding of both glycolipids is highly similar to that of α-GalCer, neither of the aromatic 
substitutions of PyrC-α-GalCer and 4ClPhC-α-GalCer insert down into the CD1d binding groove, 
as has been demonstrated for NU-α-GalCer (Figure 6). Instead, both 6”-OH aromatic substitutions 
are presented differently above the A’ pocket of CD1d. While 4ClPhC-α-GalCer does not induce a 
structural change in the A’ roof of CD1d, it interacts more intimately with CD1d. In contrast, PyrC-
α-GalCer is slightly elevated and its pyridine group contacts the TCR (Figure 6B, C). Similar to α-
GalCer, the galactose moiety of both glycolipids forms H-bonds with the TCR through the 2’’-and 
3’’-OH groups, while the 4’’-OH group looses this contact. Interestingly, it has been shown that the 
TCR contact with the 4”-OH group is the key determinant in TCR interaction (14). However, both 
PyrC-α-GalCer and 4ClPhC-α-GalCer lost the H-bond (while still making a VdW contact with 3.5 – 
3.8 Å distance) and still have similar binding affinities compared to α-GalCer, suggesting that the 
6”-OH modifications compensate in part for the loss of the 4”-OH H-bond with the TCR.  Most 
surprisingly, major van der Waals (VdW) interactions were observed between the pyridine of PyrC-
α-GalCer and the Gln52 of the TCR (Figure 6C). The pyridine makes intimate contacts with Gln52 
(distance 3.3 – 3.5 Å) compared to 6.4 – 6.9 Å for the 4Cl-phenyl group (4ClPhC-α-GalCer) and 
8.0 – 12.9 Å for the napthtyl group (NU-α-GalCer) (Figure 7). As a result, the TCR exhibits many 
more interaction with PyrC-α-GalCer than with 4ClPhC-α-GalCer or NU-α-GalCer (7) leading to 
the observed high affinity TCR binding (Table 1). Even though the pyridine ring forms extra 
contacts with Gln52 of the TCR, the binding affinity does not exceed the binding affinity of mTCR 
to α-GalCer-CD1d, likely as it lacks the important H-bond with between the 4”-OH of galactose 
and Asn30 of the TCR. Interestingly, the additional glycolipid contact with TCR residue Gln52 has 
previously not been seen in any other structure. Therefore, our data provide a structural framework 
for the design of novel α-GalCer analogs that target Gln52 to increase TCR contacts.  
Binding of 4ClPhC-α-GalCer and PyrC-α-GalCer to CD1d equals that of α-GalCer. All the H-bond 
interactions between the 2’’-OH (with Asp153) and 3’’-OH (with Asp153) of the glycolipid 
galactose and the 3-OH (with Asp80), 4-OH (with Asp 80) of the glycolipid ceramide backbone 
with CD1d residues (outlined) are conserved (Figure 6D). Carbamate linked aromatic groups of 
4ClPhC-α-GalCer and PyrC-α-GalCer, however, do not form the extra H-bond interactions between 
the carbonyl oxygen of the urea linker that connects the galactose and the naphthyl moieties with 
Thr159 of CD1d as shown in urea linked NU-α-GalCer. Thus the carbamate linker results in a more 
flexible presentation of the substituents as well as a less tight interaction of the linker itself with 
CD1d, explaining the slightly less well ordered electron density for the glycolipid 6”-OH 
modification, versus NU-α-GalCer (Figure 6B) (7). Analysis of the buried surface areas (a measure 
of the extend of how two molecules contact each other) between the glycolipids and CD1d indicates 
Fo
r P
ee
r R
ev
iew
. D
o n
ot 
dis
trib
ute
. D
es
tro
y a
fte
r u
se
.
that 4ClPhC-α-GalCer binds as extensively to CD1d as NU-α-GalCer (1,124 vs. 1146 Å2), 
correlating with their enhanced CD1d-stability (Figure 5B), while PyrC-α-GalCer (1,045Å2) and α-
GalCer (1,027 Å2) interact less extensively with CD1d (Table 2). PyrC-α-GalCer, however, 
interacts more with the TCR α–chain (199.2 Å2 vs. 137.1-155.7 Å2) and also shows an increased 
stability when bound to CD1d (Figure 5B). The increased contacts of 4ClPhC-α-GalCer are mostly 
the result of novel or increased vdW interactions with CD1d residues including Met69, Met162 and 
more importantly, Thr159 (Supplemental Table S2). Glycolipid contacts with Thr159 are not 
formed when α-GalCer or PyrC-α-GalCer bind to CD1d. 
As a result, we observe two different glycolipid binding modes compared to α-GalCer. Glycolipids 
that form increased contacts with CD1d (NU-α-GalCer and 4ClPhC-α-GalCer) and glycolipids that 
form increased contacts with the TCR (PyrC-α-GalCer).  In addition, our data suggests that the 
tested 6”-OH modified α-GalCer analogs have generally increased stability when loaded on CD1d, 
even in the absence of obvious additional molecular contacts with CD1d. In addition, our data show 
that the stability of the CD1d-carbamate glycolipid complexes is highly similar to that of NU-α-
GalCer and much higher than that of α-GalCer (Figure 5), suggesting a currently not well 
understood role of the aromatic 6”-OH modification for the overall CD1d-glycolipid stability. 
Comparison of the presentation of both carbamate-linked, as well as urea-linked aromatic 
substitutions reveals the paucity of binding orientations that are adopted by the different chemical 
groups (Figure 7). From forming a third anchor inside CD1d (NU-α-GalCer) to forming intimate 
contacts with the TCR (PyrC-α-GalCer), the aromatic groups bridge about 11 Å between the CD1d 
and TCR interface with the capacity to induce structural changes within CD1d, depending on the 
composition of the linker and aromatic substitution. 
Carbamate-pulsed BMDCs confer to strong anti-metastatic potential 
In order to determine if the new glycolipids can also mimic the anti-metastatic activity of NU-α-
GalCer, we examined their impact in the B16 lung melanoma model. Even though NU-α-GalCer 
was significantly stronger compared to α-GalCer, PyrC-α-GalCer was still superior in preventing 
tumor metastasis in the B16 lung model (Figure 8).  As little as 104 pulsed BMDCs were enough to 
exert this marked tumor response.  To analyze if this anti-tumor efficacy corresponds to strong 
cytokine responses mice were bled 16 hours after injection of 10 000 pulsed bone marrow dendritic 
cells.  Similar to the cytokine results with the high dose and the anti-metastatic results, PyrC-α-
GalCer caused significantly higher IL-12 and IFN-γ production (Figure 2 c+d).   
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Discussion 
We report the results of a novel group of 6”-OH analogs with superior Th1 polarizing potential.  
Previously described Th1 polarizing glycolipids mostly exhibited weaker antigenicity and their Th1 
polarization mainly stemmed from a much weaker Th2 cytokine production (3, 13, 47).  In contrast, 
the carbamate-analogs described here display a significantly stronger Th1 profile due to 
significantly higher IFN-γ and IL-12 production compared to α-GalCer.  Strikingly, this strong 
response was independent from the administration mode (soluble or loaded on BMDCs). 
Additionally all tested 6”-OH analogs induced a superior anti-tumor response compared to α-
GalCer.  PyrC-α-GalCer, the glycolipid which elicited the strongest cytokine response, was also 
most potent in preventing lung metastasis in a tumor model.  Crystallographic analysis from the tri-
molecular complex shows that this carbamate-analog forms increased and novel contacts with the 
TCR.  
Because several diseases are characterized by an unbalanced cytokine response, skewing the iNKT 
Th1/Th2 response can be an interesting treatment option.  Hence, understanding how glycolipid 
dependent iNKT cell activation can result in these contrasting cytokine profiles has been addressed 
by several groups and is important for the design of novel glycolipids with therapeutic properties.  
Different mechanisms both at the molecular and cellular level have been proposed. Recently, 
several reports have emphasized the stability of the CD1d-glycolipid complex to severely affect 
both the Th1 polarizing potency and the antigenicity of a glycolipid.  This has been shown for 
structurally diverse glycolipids each displaying a different mechanism for the increased stability.  
First, alteration of the lipid chains by the introduction of aromatic or cyclopropane groups enhanced 
CD1d stability strengthened Th1 responses (6, 13, 48). Second, Tyznik et al. showed that 
introduction of cyclopropane groups in both acyl and sphingosine chain enhanced CD1d stability 
(6). Third, previous research from our own group showed that addition of extra linkers to the 
galactose could make additional contacts to CD1d, which resulted in increased CD1d stability and 
significantly more potent anti-tumor properties along with a Th1 polarized response.  Fourth, 
although α-C-GalCer is a weaker antigen it was shown that its complex with CD1d had a prolonged 
half-life (5) probably because of its resistance towards enzymatic degradation by glycosidases.  Our 
results reported here show that all novel carbamate analogs form complexes with the cell surface 
CD1d that are at least as stable as those with -C-GalCer and NU-α-GalCer.  This confirms the 
importance of the stability of the CD1d-glycolipid complex in the observed Th1 bias.  Despite the 
apparent lateral binding of PyrC-α-GalCer above the A’ roof of CD1d, similar contacts are formed 
with CD1d when compared to the binding NU-α-GalCer, which binds in between the α1-α2 helix. 
Moreover, the tri-molecular structure with PyrC-α-GalCer shows novel additional contacts between 
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the TCR (residue Gln52) and the pyridine, which have previously not been seen in any other 
structure.  Therefore we believe that our data provide a structural framework for the design of novel 
α-GalCer analogs that target Gln52 to increase TCR contacts.  This enlargement of the TCR 
footprint may contribute to an enhanced stability of the tri-molecular complex and thus higher 
cytokine production.   
The cytokine production of iNKT cells themselves cannot be polarized (49). However, polarization 
of the response depends mainly on the degree of activation of bystander cells, such as NK cells.  It 
is believed that the IFN-γ which is initially produced by the iNKT cell itself, induces antigen 
presenting cells to produce IL-12 and IL-18 and subsequently drive NK cell dependent IFN-γ 
production (34, 50).  Upregulation of co-stimulatory molecules is crucial for the onset of this IL-12 
production (36, 41, 51) and plays an important role in the polarization of the iNKT cell response.  
Increased upregulation of co-stimulatory molecules might be linked to increased stability of the tri-
molecular complex because a more stable immunological synapse might have more time for 
recruitment of these molecules.  However, at present this hypothesis remains to be proven. The 
superior Th1 effect of -C-GalCer has been attributed to superior induction of CD40 and CD40L 
ligation compared to α-GalCer (3).  Our results indicate markedly increased IL-12 production along 
with an enhanced upregulation of CD40 and OX40L by PyrC-α-GalCer-pulsed-BMDC compared to 
NU-α-GalCer- and α-GalCer-pulsed-BMDCs, confirming that co-stimulation has an important role 
in expanding Th1 signalization.  Two other co-stimulatory molecules, CD80 and CD86 were 
already almost maximally upregulated with α-GalCer. Therefore, no additional increase with 6”-OH 
altered glycolipids could be observed.  This is in line with Fujii et al (2003), who found that CD80 
and CD86 expression is less essential for adjuvant characteristics of glycolipids compared to CD40 
(37). Th2 polarizing glycolipids are generally more hydrophilic and thus characterized by shorter 
lipid tails and/or insertion of unsaturated bounds into the lipid tails (2, 4, 52).   These glycolipids are 
rather loaded onto CD1d at the cell surface and additionally these hydrophilic glycolipids are 
rapidly displaced from CD1d in the lysosome (4).  In contrast, facilitated loading by lipid transfer 
proteins in the lysosome is essential for Th1 and mixed Th1/Th2 glycolipids.  Additionally, cell 
surface loading of CD1d has been associated with presentation of the CD1d-glycolipid complex 
outside of lipid rafts.  This is postulated to confer to a different immunological synapse and hence 
results, e.g. by exclusion of certain costimulatory markers and in less IFN-γ production by 
bystander NK cells (2). Although we did not specifically test the involvement of lipid rafts or 
lysosomal loading the fact that both strategies (loading onto BMDCs and soluble injection) resulted 
in a comparable Th1 polarization excludes an important role for differential loading of glycolipids.  
CD1d requires its cytoplasmic tail for recycling to the lysosome so antigen-presenting cells 
expressing the tail-deleted form of CD1d are not able to load lysosomal glycolipids.  We previously 
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found that NU-α-GalCer and α-GalCer displayed similar results when presented by antigen 
presenting cells with the tail deleted form of CD1d indicating that 6’’-derived glycolipids have a 
similar requirement for lysosomal loading as α-GalCer. Additional insertion of aromatic groups at 
the carbohydrate head moiety will probably not affect stability of the CD1d-glycolipid complex in 
the acid milieu of the lysosome because this is mainly due to lipid back bone alterations, which 
makes this unlikely to be an explanation for our results.  
In conclusion, we show that structural optimization may afford analogues that combine increased 
Th1 potency (both in mice and men) with significantly stronger anti-cancer responses.  Additionally 
PyrC-α-GalCer administration induces a 10-fold increase of IL-12 levels and is accompanied by 
increased upregulation of several costimulatory markers, which adds to its superior anti-tumor 
effect compared to NU-α-GalCer and α-GalCer.  Crystallographic analysis revealed a previously 
unknown flexibility of the NKTCR footprint and therefore opens new avenues for the synthesis of 
novel Th1 polarizing glycolipids with therapeutical potential in the cancer research.   
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Figure Legend 
Figure 1  
Th1–Th2 profile of novel glycolipids: serum cytokine levels at 16 hours after injection of 5 µg 
glycolipid (i.p.).  Graphs indicate the mean with s.e.m. of at least sixteen mice. Data are of pooled 
of two independent experiments.  (a) IFN-γ levels of α-GalCer and NU-α-GalCer are significantly 
lower (at least p<0.05 as indicated by * for α-GalCer for and # for NU-α-GalCer) compared with 
4ClPhC-, NC- and PyrC-α-GalCer (Kruskal–Wallis test, two tailed Mann-Whitney U-test), the p-
value of NC-α-GalCer compared to α-GalCer is equal to 0.0552.  (b) IL-12 levels of α-GalCer are 
significantly lower compared with 4ClPhC-, NC- and PyrC-α-GalCer (at least p<0.05 as indicated 
by * for α-GalCer for and # for NU-α-GalCer), additionally PyrC-α-GalCer induces significantly 
higher IL-12 levels (p<0.001). (Kruskal–Wallis test, two- tailed Mann–Whitney U-test). 
Figure 2  
Th1–Th2 profile of novel glycolipids loaded on BMDCs (20h, 100 ng/mL): serum cytokine 
levels at different time points after injection of glycolipid pulsed BMDCs.  Graphs indicate the 
mean with s.e.m. of at least sixteen mice. Data are of pooled of two independent experiments.  (a) 
After injection of 600 000 glycolipid-pulsed BMDCs IFN-γ levels of 4ClPhC- and PyrC-α-GalCer 
are both at 16 and 24 hours significantly higher compared to NU-α-GalCer.  NU-α-GalCer also 
induces IFN-γ levels that are significantly higher compared to α-GalCer both at 16 and 24 hours 
after injection. (at least p<0.05 as indicated by * for α-GalCer for and # for NU-α-GalCer) 
(Kruskal-Wallis test and two-tailed Mann-Whitney U test).  (b) After injection of 600 000 
glycolipid-pulsed BMDCs, IL-12 levels of PyrC-α-GalCer are both at 16 and 24 hours significantly 
higher compared to NU-α-GalCer. NU-α-GalCer and 4ClPhC also induce IFN- levels that are 
significantly higher compared to α-GalCer at 16 hours after injection. (p<0.001 as indicated by * for 
α-GalCer for and # for NU-α-GalCer) (Kruskal-Wallis test and two-tailed Mann-Whitney U test).  
(c) + (d) Both IFN-γ and IL-12 levels are significantly higher 16 hours after injection of only 10 000 
PyrC-pulsed BMDCs compared to NU-α-GalCer and α-GalCer. (at least p<0.01 as indicated by * 
for α-GalCer for and # for NU-α-GalCer) (Kruskal-Wallis test and two-tailed Mann-Whitney U 
test) 
Figure 3  
Cytokine levels in supernatant of co-culture of human iNKT cells and glycolipid-loaded 
irradiated PBMC. Results shown are pooled data from two independent experiments using cells 
from two different donors. (a) Analysis of Th2 cytokines shows less production of IL-13 and IL-4 
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for PyrC-α-GalCer compared to α-GalCer stimulated iNKT cells (Mann-Whitney U test p=0.02 for 
IFN-γ and ns for IL-4). (b) In contrast, IFN-γ and IL-12 production are slightly elevated with PyrC-
α-GalCer compared to α-GalCer (Mann-Whitney U test p=0.03 for IFN-γ and p=0.05 for IL-12). 
Figure 4  
In vitro stimulation of an iNKT cell line with 6’-OH altered glycolipids bound to bone 
marrow-derived dendritic cells (BMDCs). BMDCs were grown with GM-CSF for 10 days and 
subsequently loaded with a glycolipid (100 ng/ml) for 20 h. (a) Co-culture with an iNKT cell line 
(2C12) was set up for 16 hours and IL-2 production was measured by ELISA. 4ClPhC-, NC-, PyrC-
α-GalCer, and NU-α-GalCer significantly differ from α-GalCer (p<0.01) (two- tailed Mann–
Whitney U-test). Data are shown as mean with s.e.m. (n=6). One representative of seven 
independent experiments. (b) TCR expression by the iNKT cell line (2C12) 24 hours after 
coculture with glycolipid-pulsed CD45.1 BMDCs.  iNKT cells were selected as CD45.2 positive, 
CD45.1 negative and 7AAD negative.  All 6”-OH altered glycolipids including α-C-GalCer show 
clear TCRb downregulation.  One representative experiment of two independent experiments. (c) 
Intracellular IL-2 production by 2C12 cells, 4 hours after coculture.  One representative  of two 
independent experiments. 
Figure 5  
Analysis of stability of the glycolipid-CD1d complex (a) Bone marrow dendritic cells were first 
loaded during 20 hours with 100 ng/mL glycolipid.  Hereafter the glycolipid was washed away, 
cells were left in appropriate medium for several time intervals (ranging form 4 h to 48 h, see X-
axis).  Medium with glycolipid that might have come off CD1d was washed away and coculture 
with 2C12 cells (iNKT cell hybridoma).  IL-2 production in the medium was used as a surrogate 
marker for glycolipid-loaded CD1d complexes. (b) Data from (a) were normalized to the 4 hour 
time point.  Represents stability of each glycolipid towards CD1d. Data are shown as mean with 
s.e.m. (n = 6). One representative of two independent experiments.  
Figure 6  
Crystal structure of the mCD1d-4ClPhC-α-GalCer-mTCR and mCD1d-PyrC-α-GalCer-
mTCR ternary complexes. (a) Overview of the representative ternary complex containing PyrC-α-
GalCer. PyrC-α-GalCer is shown in orange, mCD1d heavy chain in grey and β2m in purple. TCR α 
chain is shown in cyan and TCR β chain is shown in orange. (b) Final 2Fo-Fc electron density map 
is shown as blue mesh, contoured at 1.0 σ level for the glycolipid PyrC-α-GalCer (upper panel) and 
for 4ClPhC-α-GalCer (lower panel, in yellow). Note that α2-helix is removed for clarity. (c) TCR 
glycolipid contacts illustrate the additional TCR contact between the Q52 and the nitrogen of the 
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aromatic group of PyrC-α-GalCer (top panel), while both ligands lack the H-bond between 4’-OH 
of galactose with N30 of TCR. Hydrogen bonds are indicated as dotted lines. While the 4ClPhC-α-
GalCer assumes a more intimate position with CD1d (lower panel), PyrC-α-GalCer is tilted upward 
to interact more closely with the TCR (upper panel). (d) H-bond interactions between mCD1d and 
both glycolipids is conserved.  
Figure 7  
Binding comparison of Th1-skewing NKT cell antigen. Superimposing the structures of mCD1d-
α-GalCer-mTCR (PDB code 3HE6, purple), mCD1d-NU-GalCer-mTCR (PDB code 3QUZ, green), 
mCD1d-PyrC-α-GalCer-mTCR (PDB code 4IRS, orange) and mCD1d-4ClPhC-α-GalCer-mTCR 
(PDB code 4IRJ, yellow) complexes indicate differences in accommodating the 6’-OH substitutions 
of each glycolipid. Carbamate linked functional groups are situated laterally above the CD1d 
binding group (4ClPhC-α-GalCer) or tilted toward the TCR (PyrC-α-GalCer), while NU-α-GalCer 
is inserted into the CD1d binding group.  
Figure 8 
Tumor suppression by iNKT cell stimulation in a B16 melanoma lung metastasis model.  (a) 
When 10 000 BMDCs loaded with glycolipid were injected, all 6’-OH altered glycolipids are able 
to reduce the quantity of lung nodules significantly more than α-GalCer. Additionally PyrC-α-
GalCer is able to reduce the amount of noduli even significantly better.  Each dot represents an 
individual mouse with at least 8 mice/group. Data are representative of two independent 
experiments. Error bars express mean and Kruskal-Wallis test and one-sided Student t-test was used 
for statistical analysis. (b) Pictures of lungs that were used for analysis in (a).  Each lung is 
representative for the specific glycolipid as the lung with the amount of lung noduli that is the 
closest to the mean (number in the left corner) are represented here. 
Table I 
TCR binding kinetics 
Table II 
Buried surface areas between TCR-CD1d and glycolipid (in Å2) 
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ii Structure factors and coordinates have been deposited in Protein Data Bank 
(www.rcsb.org) under accession code 4IRJ (4ClPhC-alpha-GalCer), 4IRS (PyrC-alpha-
GalCer). 
 
Abbreviations used in this paper: BMDC: bone marrow dendritic cell, NKT cell: natural 
killer T cell, NKTCR: NKT cell T cell receptor; α-GalCer : alpha galactosyl ceramide, 
4ClPhC-α-GalCer: α-GalCer-6”-(4-chlorophenyl)carbamate, NC-α-GalCer: α-GalCer-6”-(1-
naphthyl)carbamate, NU-α-GalCer: α-GalCer-6”-(1-naphthyl)urea, PyrC-α-GalCer: α-
GalCer-6”-(pyridin-4-yl)carbamate 
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Table 1. TCR binding kinetics 
 
glycolipid KD [nM] kon [M-1s-1] koff [s-1]  
α-GalCer 26.45±4.6 5.06±0.66104 1.34±0.0910-3  
4ClPhC-α-GalCer 49.3±0.3  5.27±1.47104 2.62±0.7210-3  
NC-α-GalCer 37.1±14 3.83±0.53104 1.5±0.07410-3  
PyrC-α-GalCer 25.0±3 6.61±1.21104 1.61±0.0110-3  
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Table 2. Buried surface areas between TCR-CD1d and glycolipid (in Å3) 
 
 CD1d-ligand-TCR complex 
Contact surfaces α-GalCer1 NU-α-GalCer 4ClPhC-α-GalCer PyrC- α-GalCer
CD1d-ligand 1,027 1,146 1,124 1,045 
TCRα-ligand 137.1 146.2 155.7 199.2 
TCRα-CD1d 433.4  427.9 436.3 434.9 
TCRβ-CD1d1 192.6 324.0 298.9 319.3 
TCRαβ-CD1d1 626 751.9 735.2 754.2 
1CDR3β sequence of the TCR found in the α-GalCer complex is different from CDR3β 
sequence found in all other structures and lacks contacts with CD1d. Therefore, contact 
surfaces TCRβ-CD1d and TCRαβ-CD1d are smaller.  
